Pharmacology, Toxicology and Pharmaceutical Science
Amikacin
100%
Pseudomonas aeruginosa
83%
Prevalence
83%
Pneumonia
83%
Acinetobacter
83%
Imipenem
66%
Ceftazidime
66%
Vancomycin
50%
Escherichia coli
50%
Antimicrobial Resistance
50%
Ampicillin
50%
Methicillin-Resistant Staphylococcus Aureus
50%
Antiinfective Agent
33%
Penicillin G
33%
Carbapenem
33%
Organisms
16%
Epidemiology
16%
Penicillinase
16%
Klebsiella pneumoniae
16%
Quinolone Derivative
16%
Enterococcus faecium
16%
Cefoxitin
16%
Cephalosporin
16%
Salmonella
16%
Streptococcus Pneumoniae
16%
Multiple Drug Resistance
16%
Nursing and Health Professions
Amikacin
100%
Prevalence
83%
Pneumonia
83%
Hospital
83%
Laboratory
83%
Imipenem
66%
Ceftazidime
66%
Antimicrobial Resistance
50%
Methicillin-Resistant Staphylococcus Aureus
50%
Ampicillin
50%
Vancomycin
50%
Antiinfective Agent
33%
Carbapenem
33%
Penicillin G
33%
Quinolone Derivative
16%
Epidemiology
16%
Cephalosporin
16%
Penicillinase
16%
Procedures
16%
Device Material
16%
Patient
16%
Cefoxitin
16%
Species
16%
Ward
16%
Drug Development
16%
Biochemistry, Genetics and Molecular Biology
Amikacin
100%
Prevalence
83%
Acinetobacter
83%
Pseudomonas aeruginosa
83%
Ceftazidime
66%
Imipenem
66%
Escherichia coli
50%
Methicillin Resistant Staphylococcus Aureus
50%
Antibiotic Resistance
50%
Vancomycin
50%
Ampicillin
50%
Penicillin
33%
Organisms
16%
Multidrug Resistance
16%
Klebsiella pneumoniae
16%
Salmonella
16%
Cefoxitin
16%
Species
16%
Streptococcus Pneumoniae
16%
Enterococcus faecium
16%
Development
16%
Spectrum
16%
Comprehension
16%
Immunology and Microbiology
Prevalence
83%
Pseudomonas aeruginosa
83%
Acinetobacter
83%
Escherichia coli
50%
Methicillin-Resistant Staphylococcus Aureus
50%
Antimicrobial Resistance
50%
Penicillin
33%
Pneumococcus
33%
Organisms
16%
Streptococcus Pneumoniae
16%
Salmonella
16%
Klebsiella pneumoniae
16%
Multidrug Resistance
16%
Enterococcus faecium
16%
Species
16%
Development
16%
Comprehension
16%
Spectrum
16%